Raltegravir with optimized background therapy for resistant HIV-1 infection.

BACKGROUND Raltegravir (MK-0518) is an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase active against HIV-1 susceptible or resistant to older antiretroviral drugs. METHODS We conducted two identical trials in different geographic regions to evaluate the safety and efficacy of raltegravir, as compared with placebo, in combination with optimized background therapy, in patients infected with HIV-1 that has triple-class drug resistance in whom antiretroviral therapy had failed. Patients were randomly assigned to raltegravir or placebo in a 2:1 ratio. RESULTS In the combined studies, 699 of 703 randomized patients (462 and 237 in the raltegravir and placebo groups, respectively) received the study drug. Seventeen of the 699 patients (2.4%) discontinued the study before week 16. Discontinuation was related to the study treatment in 13 of these 17 patients: 7 of the 462 raltegravir recipients (1.5%) and 6 of the 237 placebo recipients (2.5%). The results of the two studies were consistent. At week 16, counting noncompletion as treatment failure, 355 of 458 raltegravir recipients (77.5%) had HIV-1 RNA levels below 400 copies per milliliter, as compared with 99 of 236 placebo recipients (41.9%, P<0.001). Suppression of HIV-1 RNA to a level below 50 copies per milliliter was achieved at week 16 in 61.8% of the raltegravir recipients, as compared with 34.7% of placebo recipients, and at week 48 in 62.1% as compared with 32.9% (P<0.001 for both comparisons). Without adjustment for the length of follow-up, cancers were detected in 3.5% of raltegravir recipients and in 1.7% of placebo recipients. The overall frequencies of drug-related adverse events were similar in the raltegravir and placebo groups. CONCLUSIONS In HIV-infected patients with limited treatment options, raltegravir plus optimized background therapy provided better viral suppression than optimized background therapy alone for at least 48 weeks. (ClinicalTrials.gov numbers, NCT00293267 and NCT00293254.)

[1]  J. Church.  Raltegravir With Optimized Background Therapy for Resistant HIV-1 Infection , 2009, Pediatrics.

[2]  J. Goldman.  Treatment strategies for CML. , 2009, Best practice & research. Clinical haematology.

[3]  D. Hazuda,et al.  Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. , 2008, The New England journal of medicine.

[4]  E. Poveda,et al.  Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. , 2007, The Journal of antimicrobial chemotherapy.

[5]  C. Crumpacker,et al.  Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection: Results of a 48-Week Controlled Study , 2007, Journal of acquired immune deficiency syndromes.

[6]  C. Katlama,et al.  Safety and Efficacy of Darunavir (TMC114) With Low-Dose Ritonavir in Treatment-Experienced Patients: 24-Week Results of POWER 3 , 2007, Journal of acquired immune deficiency syndromes.

[7]  I. Mcintosh,et al.  Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase Enzyme , 2007, Drug Metabolism and Disposition.

[8]  M. Hughes,et al.  Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. , 2007, The Journal of infectious diseases.

[9]  R. Haubrich,et al.  Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial , 2007, The Lancet.

[10]  M. Falster,et al.  Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis , 2007, The Lancet.

[11]  Anne-Mieke Vandamme,et al.  No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[12]  J. Eron,et al.  Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients , 2007, AIDS.

[13]  C. Katlama,et al.  Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial , 2007, The Lancet.

[14]  P. Cahn,et al.  Raltegravir: a new antiretroviral class for salvage therapy , 2007, The Lancet.

[15]  F. Aubin,et al.  Cervical intraepithelial neoplasia associated with epidermodysplasia verruciformis HPV in an HIV-infected patient: a manifestation of immune restoration syndrome. , 2007, European journal of dermatology : EJD.

[16]  J. Pitt,et al.  Time Trends for HIV-1 Antiretroviral Resistance Among Antiretroviral-Experienced and Naive Pregnant Women in New York City During 1991 to Early 2001 , 2007, Journal of acquired immune deficiency syndromes.

[17]  C. Katlama,et al.  Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1 , 2007, AIDS.

[18]  C. Kovacs,et al.  Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals , 2006, Journal of acquired immune deficiency syndromes.

[19]  S. Spector,et al.  Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study. , 2006, The Journal of infectious diseases.

[20]  Olga M. Klibanov,et al.  Three-class antiretroviral resistance in a patient with acute HIV-1 infection. , 2006, AIDS patient care and STDs.

[21]  K. Hertogs,et al.  Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistance , 2006, Current medical research and opinion.

[22]  A. Savarino.  A historical sketch of the discovery and development of HIV-1 integrase inhibitors , 2006, Expert opinion on investigational drugs.

[23]  C. Farthing,et al.  Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  F. Antunes,et al.  Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  W. Mcfarland,et al.  Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance , 2006, AIDS.

[26]  Michael S Saag,et al.  Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. , 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[27]  D. Reich,et al.  Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients , 2006, Neurology.

[28]  E. Poeschla,et al.  Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults. , 2006, The Lancet. Infectious diseases.

[29]  Matthew A. Meier,et al.  Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  M. Wainberg,et al.  Effects of drug resistance on viral load in patients failing antiretroviral therapy , 2006, Journal of medical virology.

[31]  J. Hornberger,et al.  Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States. , 2006, AIDS research and human retroviruses.

[32]  A. Blaxhult,et al.  Concomitant Use of an Active Boosted Protease Inhibitor with Enfuvirtide in Treatment-Experienced, HIV-Infected Individuals: Recent Data and Consensus Recommendations , 2006, HIV clinical trials.

[33]  Michael P. Busch,et al.  Trends in Antiretroviral Drug Resistance and Clade Distributions Among HIV-1--Infected Blood Donors in Sao Paulo, Brazil , 2006, Journal of acquired immune deficiency syndromes.

[34]  D. Pillay,et al.  Evolution of Transmitted HIV-1 with Drug-Resistance Mutations in the Absence of Therapy: Effects on Cd4+ T-Cell Count and HIV-1 Rna Load , 2006, Antiviral therapy.

[35]  P. Easterbrook,et al.  Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  P. Narciso,et al.  Drug-Class-Wide Resistance to Antiretrovirals in HIV-Infected Patients Failing Therapy: Prevalence, Risk Factors and Virological Outcome , 2005, Antiviral therapy.

[37]  Michael S Saag,et al.  Treatment for Adult HIV Infection 2006 Recommendations of the International AIDS Society–USA Panel , 2006 .

[38]  M. Wainberg,et al.  HIV transmission and primary drug resistance. , 2006, AIDS reviews.

[39]  A. Gładysz,et al.  Lung cancer as an immune reconstitution disease in an HIV-1 positive man receiving HAART. , 2006, Postepy higieny i medycyny doswiadczalnej.

[40]  M. Jelen,et al.  Non-Hodgkin's lymphoma as a rare manifestation of immune reconstitution disease in HIV-1 positive patients. , 2006, Postepy higieny i medycyny doswiadczalnej.

[41]  A. Luber.  Treatment strategies for highly treatment-experienced HIV-infected patients , 2005, Expert review of anti-infective therapy.

[42]  C. Tinelli,et al.  A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  Erik De Clercq,et al.  Emerging anti-HIV drugs. , 2005 .

[44]  M. Weichenthal,et al.  Malignant Melanoma and HIV Infection – Aggressive Course despite Immune Reconstitution , 2004, Oncology Research and Treatment.

[45]  D. Hazuda,et al.  Integrase Inhibitors and Cellular Immunity Suppress Retroviral Replication in Rhesus Macaques , 2004, Science.

[46]  Terri Wrin,et al.  The prevalence of antiretroviral drug resistance in the United States , 2004, AIDS.

[47]  G. Dickinson,et al.  Development of Anti‐Retroviral Resistance of HIV‐1 Infected Individuals on Therapy: Is it inevitable? , 2004, IUBMB life.

[48]  M. Battegay,et al.  Immune reconstitution in HIV-infected patients. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  M. Leal,et al.  Genotypic resistance profile in treatment-experienced HIV-infected individuals after abacavir and efavirenz salvage regimen. , 2004, Antiviral research.

[50]  Martin S. Hirsch,et al.  Treatment for adult HIV infection. , 2004 .

[51]  D. Scadden,et al.  Immune reconstitution in HIV infection and its relationship to cancer. , 2003, Hematology/oncology clinics of North America.

[52]  Christine Katlama,et al.  Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. , 2003, The New England journal of medicine.

[53]  J. Montaner,et al.  Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. , 2003, The New England journal of medicine.

[54]  R. Gulick.  New antiretroviral drugs. , 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[55]  T. Powles,et al.  Immune Reconstitution Inflammatory Syndrome Mimicking Relapse of AIDS Related Lymphoma in Patients with HIV 1 Infection , 2003, Leukemia & lymphoma.

[56]  J. Tolson,et al.  Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy. , 2001, AIDS research and human retroviruses.

[57]  F. Maggiolo,et al.  Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution , 2001, International journal of STD & AIDS.

[58]  M C Weinstein,et al.  The cost effectiveness of combination antiretroviral therapy for HIV disease. , 2001, The New England journal of medicine.

[59]  M. Wainberg,et al.  Resistance Profiles to Antiretroviral Drugs in HIV-1 Drug-Naive Patients in Argentina , 2001, Antiviral therapy.

[60]  Amy S. Espeseth,et al.  HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[61]  M. Kazatchkine,et al.  The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patients. , 2000, Antiviral research.

[62]  J A Grobler,et al.  Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. , 2000, Science.

[63]  Richard D Moore,et al.  Costs of HIV medical care in the era of highly active antiretroviral therapy. , 1999, AIDS.

[64]  E. Vittinghoff,et al.  Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. , 1999, The Journal of infectious diseases.

[65]  T. Perneger,et al.  Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. , 1999, AIDS.

[66]  JD Lundgren,et al.  Changing patterns of mortality across Europe in patients infected with HIV-1 , 1998, The Lancet.

[67]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[68]  V. Calvez,et al.  Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease , 1998, The Lancet.

[69]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[70]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. , 1997, JAMA.

[71]  J. Peters.  Treatment strategies. , 1997, Community nurse.